Join this interprofessional panel as they discuss the management of triple-negative breast cancer using immunotherapeutic agents.

The goal of this initiative is to improve the knowledge and competence of oncologists, nurses/nurse practitioners (NPs), and pharmacists in safely and effectively implementing immune checkpoint inhibitors for eligible patients with triple-negative breast cancer (TNBC).

This activity is intended for oncologists, obstetricians and gynecologists, pathologists, nurses, and pharmacists.

Learning Objectives:

• Have increased knowledge regarding the
  • Clinical trial data on the use of immune checkpoint inhibitor (ICI) regimens in patients with triple-negative breast cancer (TNBC) across the spectrum of disease
• Have greater competence related to
  • Identifying patients who may be appropriate candidates for checkpoint inhibition
  • Using a team-based approach to managing immune-related adverse events of ICIs in TNBC

Approximate Time to Complete: 45 minutes

Credit Available: May 7, 2021 - May 7, 2022

Developed through a partnership between SITC and Medscape.

Additional Resources for Clinicans from SITC: